FUJIFILM: Large-scale manufacturing base for biopharmacy: Newly established in the United States
January 07, 2021
FUJIFILM:
We will make a large-scale investment of over 200 billion yen.
Established a large manufacturing base for biopharmacy in the United States.
Supports mass production of APIs,
From API manufacturing to formulation,
One-site, one-stop contracting for packaging
FUJIFILM Diosynth Biotechnologies:
FUJIFILM Diosynth Biotechnologies (FDB), the core company of biopharmacy CDMO (* 2)
The new base will be operational in the spring of 2025.
FUJIFILM:
Currently, we are developing business at 4 FDB bases.
United States (North Carolina, Texas)
United Kingdom (Billingham City)
In Denmark (Hillrod City)
We are expanding the contract development and manufacturing business of biopharmacy.
Biopharmacy production:
Antibody drugs and hormone preparations,
Gene therapy drug,
Vaccines etc.
We will develop production processes for all types of biopharmacy and take advantage of our strength in handling contract manufacturing from APIs to formulations and packaging.
Nihon Keizai Shimbun
https://www.nikkei.com/article/DGXLRSP602770_X00C21A1000000/
Fujifilm to Invest Over 200 Billion yen (2 Billion USD) to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals in the U.S.A.
TOKYO, January 7, 2021
FUJIFILM Corporation (President: Kenji Sukeno)
is making an investment of more than 200 Billion yen (2 Billion USD) to establish a new large-scale cell culture production site in the United States to accelerate the growth of its biopharmaceutical contract development and manufacturing business (CDMO).
FUJIFILM Diosynth Biotechnologies,
a subsidiary of FUJIFILM Corporation,
with development and manufacturing facilities across the U.S.A., U.K., and Denmark will operate the new facility.
This new facility
will offer large-scale cell culture manufacturing of bulk drug substance with 8 x 20,000L bioreactors (physical volume), with the potential to expand and add a further 24 x 20,000L bioreactors based on market demand.
In addition to drug substance manufacture, the facility
will also provide commercial scale, automated fill-finish and assembly, packaging and labeling services.
The new site
will be built within the vicinity of an existing Fujifilm site, and is scheduled to begin operations in the spring of 2025.
Fujifilm Global